Skip to main content

Table 10 HIV/AIDS

From: Benefits and harms of medical cannabis: a scoping review of systematic reviews

Author, year {refid} Search dates; # databases searched Funding source Nstudies Illness/condition Intervention/comparator Outcomes Conclusions from data AMSTAR-2 rating
Lutge, 2013 [48] 1980–Jul 2012; 7 NR 7 HIV/AIDS I: Plant-based and synthetic cannabinoids
C: Placebo
• Change in body fat
• Appetite
• Food/caloric intake
• Nausea and vomiting
• Performance
• Mood
• Subjective experience of drug
• Peripheral NP
• Effect on pharmacokinetics of protease inhibitors
• Viral load and CD4 count
• Resting heart rate
• Skin temperature
• Withdrawal due to adverse events
Reported SBS for all outcomes except change in mood, which found no statistically significant difference between groups M
Phillips, 2010 [53] Search on Jun 20, 2008 and updated Feb 22, 2010; 4 Non-profit 2 HIV I: Plant-based cannabis
C: placebo
• NP Favors intervention CL
Merlin, 2016 [67] Inception to Jan 2015; CENTRAL: Jun 2014; 5 Government 1 HIV I: Plant-based cannabis
C: Placebo
• NP Reported SBS CL
  1. NP neuropathic pain, NR not reported, SBS study-by-study